Εκπαιδευτικά προγράμματα
Λίστα αντικειμένων

Goal: Our current research paper in CLL published in Blood
Advances was presented. Further goals were discussed.
Presenter: Prof. Spyridonidis.
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.


Goal: To learn how to calculate EFS,OS, TRM, how to create
Kaplan Meier curves and CI curves. The difference between CI and
Kapolan Meier was discussed.
Corresponding literature from ALPWP EBMT is provided.
Presenter: Prof. Spyridonidis.
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas.


Goal: To learn the differences between RIC, RTC, MAC, NMA,
etc.
Corresponding literature is provided.
Presenter: Prof. Spyridonidis.
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas


Goal: To learn how to deceide whether we should get an older
person to transplant. Literature and cases are presented.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou.


Goal: To understand the structure of donor registries. Learn
corresponding terminology.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou.


Goal:To learn about Bite, inotuzumab and CART therapies.
Presenter: Prof. Spyridonidis.
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas


Goal: Which graft is better to use in haplo PTCY transplant?
Dr Liga presented the current literature. We deceide the
following policy CR-1 BM, advanced disease PBSC.
Presenter: Dr Liga
Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou.


Goal: An overview of the haplo PTCY platform.
Presenter: Dr Liga.
Participants: Prof. Spyridonidis, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou.


Goal: Principles of Donor selection.
Quiz and examples were shown.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Triantafyllou


Goal: to get an overview of current cellular therapies and learn
where we stand.
Presenter: Prof. Spyridonidis
Participants: Dr Liga, Dr Spyridis, Dr Aggelinas, Dr
Triantafyllou


a reent study publisghed at LEukemia confirms the role of
upfront ASCT in MM. Upfornt autolgous is the standrd of care in
MM
Presenter: Spyridonidis
Patriciapnts: all medical staff


The FDA approved tisagenlecleucel (Kymriah) for certain paediatric
and young adult patients with B-cell acute lymphoblastic leukaemia
(ALL).
The cell-based gene therapy is approved in the United States for
the treatment of patients up to 25 years of age with B-cell
precursor ALL that...


Combined use of global and targeted analyses allows the cytogenetic
classification of
88% of adult patients with Ph-negative BCP-ALL.
• In GRAALL trials, t(4;11)/KMT2A-AFF1 and t(v;14q32)/IGH are the
two cytogenetic
anomalies significantly associated with a worse outcome.
Combined use of global and targeted analyses allows the
cytogenetic...


We often see such patients and the question is raised whether
transplant could help these poatients. A rertrospetive analysis
from the Italian transplant centers tries to answer this. There ia
an accompayiong editorial on this analysis.
Presenter: Spyridonidis
participants: all medical staff


Venetoclax Gets Breakthrough-Therapy Designation for
AML
At 12-month follow-up, the overall response rate was 44 percent
(complete remission, n=4; complete remission without complete
marrow recovery, n=4; resistant disease, n=8; death before
evaluation, n=2).
FDA Approves Combination Daunorubicin and Cytarabine for
High-Risk AML
The drug was approved based on...


Wediscussed the incidence and diagnosis of IDH mutations in AML.
The new approved drug may prove very helpful for these patients
Presenter: Spyridonidis
Participants: all medical staff
The US Food and Drug Administration (FDA) has approved enasidenib
(Idhifa) for the treatment of relapsed or refractory...


Extended analysis of the fiorst randomized ATG trial in BMT.
Presenter: Spyridonidis
Participants: All medical staff


Excellent paper by John Dicks group published in Nature. The
study identifies the reasosn why some aptrients relapse also
amny years after chemothertpay or allogheneic BMT.
Presenter: Spyridonidis
Participants: All medical staff


An intersting study showed a correaltion between CHIP and
atherpscleorosis.
We discussed the CHIP.
Presenter Spyridonidis
Participants: all medical staff


